Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...

Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small ...

Dec 23 (Reuters) - A patient who was being treated with Pfizer's (PFE.N), opens new tab hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the ...

Pfizer (PFE) on Tuesday announced that a patient who was taking part in a long-term extension trial for its hemophilia therapy Hympavzi (marstacimab) died after serious adverse events. The patient ...

What was the challenge that you saw at Pfizer that you wanted to address? The challenge was creating continuity in patient insights given the scope and scale of the organization itself. How do we do ...

Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and entertainment news.

FILE PHOTO: A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025. REUTERS/Mike Blake/File Photo Dec 23 (Reuters) - A ...